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The History of Mycoplasma
pneumoniae Pneumonia
Takeshi Saraya*
Department of Respiratory Medicine, Kyorin University School of Medicine, Mitaka, Japan
In the United States in the 1930s, although the pathogen was not known, atypical
pneumonia was clinically distinguished from pneumococcal pneumonia by its resistance
to sulfonamides. Reimann (1938) reported seven patients with an unusual form of
tracheo bronchopneumonia and severe constitutional symptoms. He believed the
clinical picture of this disease differed from that of the disease caused by influenza
viruses or known bacteria and instead suspected “primary atypical pneumonia.” For
many years, the responsible infectious agent was tentatively classified as a filterable
virus that could pass through a Seitz filter to remove bacteria and was reported
to be a psittacosis-like or new virus. After that, Eaton et al. (1942, 1944, 1945)
identified an agent that was the principal cause of primary atypical pneumonia using
cotton rats, hamsters, and chick embryos. Eaton et al. (1942, 1944, 1945) did not
perform an inoculation study in human volunteers. During the 1940s, there were
three groups engaged in discovering the etiology of the primary atypical pneumonia.
(1) Commission on Acute Respiratory Diseases Diseases directed by John Dingle,
(2) Dr. Monroe Eaton’s group, the Virus Research Laboratory of the California State
Public Health Department, (3) The Hospital of the Rockefeller Institute for Medical
Research directed by Horsfall. During 1940s, the members of the Commission on
Acute Respiratory Diseases concluded that the bacteria-free filtrates obtained from
the patients, presumably containing a virus, could induce primary atypical pneumonia
in human volunteers via Pinehurst trials. During 1950s, serological approaches for
identification of the Eaton agent developed such as Fluorescent-Stainable Antibody,
and at the beginning of the1960s, the Eaton agent successfully grew in media, and
finally accepted as a cause of primary atypical pneumonia. Thus, technical difficulties
with visualizing the agent and failure to recognize the full significance of the Pinehurst
transmission experiments resulted in a lapse of 20 years before acceptance of the Eaton
agent as Mycoplasma pneumoniae. This review describes the history of M. pneumoniae
pneumonia with a special focus on the recognition between the 1930 and 1960s of the
Eaton agent as the infectious cause.
Keywords: Mycoplasma pneumoniae pneumonia, Eaton agent, Pinehurst trials, primary atypical pneumonia,
history
INTRODUCTION
Atypical bacterial pneumonia is caused by atypical organisms that are not detectable on
Gram stain and cannot be cultured using standard methods, and characterized by a symptom
includes headache, low-grade fever, cough, and malaise. The most common organisms are
Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. The history
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of C. pneumoniae began in Taiwan in 1965, which was first
isolated from the eye of a child in a trachoma vaccine study and
first isolated from the respiratory tract in 1983 from a University
of Washington student (Grayston et al., 1986; Grayston, 2000).
Among them, M. pneumoniae is one of the leading causes
of community acquired pneumonia. The term mycoplasma
emerged in the 1950s and means “mykes” (fungus) and “plasma”
(formed) in Greek. Isolation of the first mycoplasma was the
bovine pleuropneumonia agent, now known as M. mycoides
subsp. mycoides, which was reported initially in Nocard and
Roux (1898). This bacterium became to know over the next
50 years as pleuropneumonia-like organisms (PPLO) in various
animals. Dienes and Edsall (1937) detected first Mycoplasma
isolated from humans in a Bartholin’s gland abscess, known
as M. hominis. Regarding with M. pneumoniae, it was first
isolated in tissue culture from the sputum of a patient with
primary atypical pneumonia by Eaton et al. (1944) as Eaton agent.
However, its taxonomy remained obscure until the early 1960s
when it was clearly identified as a bacterium. The cell volume of
M. pneumoniae, is less than 5% of that of a typical bacillus and
rarely exceed 100 µm in diameter. M. pneumoniae, lacks a cell
wall, which makes it intrinsically resistant to antimicrobials, such
as β-lactams. In this regards, identification of the M. pneumoniae
was a challenging issue for pioneers. This review focus on the
history of discovering and acceptance the Eaton agent as the
cause of primary atypical pneumonia.
ATYPICAL PNEUMONIA-DISCOVERY OF
A NEW CLINICAL SYNDROME (1940s)
Reimann (1938, 1984) reported several patients with similar
clinical features such as mild symptoms of hoarseness, sore
throat, pyrexia with relative bradycardia, and persistent dry
cough. The fever lasted from 10 to 43 days in the cases
of severe involvement but most typically only lasted about
3 weeks. He believed that those symptoms were strikingly
similar to those of patients in a report by Scadding (1937)
from London, characterized as gradual onset, malaise, shivering,
dyspnea, dry cough, marked sweating, slight leukocytosis, and
roentgenographic shadows of diffuse pneumonia. Reimann also
indicated that colleagues in other East Coast cities had recognized
this syndrome, but it was usually diagnosed as influenza.
Indeed, Meiklejohn et al. described primary atypical
pneumonia as being caused by psittacosis-like viruses
(Meiklejohn et al., 1944) and/or a new atypical pneumonia
virus (Meiklejohn et al., 1945). Around the same time, Dingle
described that primary atypical pneumonia of unknown etiology
was a more common disease than previously thought (Finland
and Dingle, 1942).
DISCOVERY OF THE EATON AGENT AND
ASSOCIATED ANIMAL MODELS
Eaton et al. (1942) (Figure 1) also reported that an infectious
agent obtained from a total of 78 patients with atypical
FIGURE 1 | Photograph of Dr. Eaton Eaton, Monroe D., U.S.
microbiologist, 1904–1958. The photograph of Dr. Eaton in the manuscript
(Rev Infect Dis, 12, 338–353), which taken in the early 1960s and reprinted
permission was obtained.
pneumonia was apparently transmissible to cotton rats. Most
of the inoculation materials were retrieved from sputum or
lung samples from patients with atypical pneumonia and were
intranasally inoculated to the cotton rats. Among the total of
131 cotton rats receiving material, 35 developed pneumonia and
lung lesions described as patchy and reddish-gray with maximum
intensity of illness at 6–8 days after inoculation. The etiological
agent was presumably a filterable virus as large as 180–250 µm
(infectivity was retained by a membrane of an average pore
diameter of 300 µm) that differed from the psittacosis-like virus
or other known viruses that were known to infect cotton rats by
the intranasal route.
Eaton et al. (1944) demonstrated that both infected chick
embryo tissues and instillation of infective human material
(sputum from 128 persons having atypical pneumonia and
lung tissue from 15 patients who had died of the disease)
generated similar pulmonary lesions in the animal models of
cotton rats and hamsters. In addition, the agent propagated
in chick embryos was specifically neutralized by serum from
patients who had recovered from primary atypical pneumonia
but was not neutralized by acute phase specimens (Eaton et al.,
1944).
Eaton (1950) studied antibiotic therapy in his virus-infected
cotton rats and described that the agents causing primary atypical
pneumonia were sensitive to aureomycin but were somewhat
smaller than viruses of the psittacosis-lymphogranuloma group,
which were also inhibited by this drug. Unfortunately, however,
the virus inoculated into human volunteers was not studied for its
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ability to grow in chicken embryos, and no inoculations of human
volunteers were performed with either the virus propagated in
chick embryos or chick embryo lung suspensions infected with
the Eaton agent. Thus, the organism was identified in Eaton et al.
(1944) but its taxonomy remained obscure until the early 1960s
when it was clearly identified as a bacterium.
PINEHURST TRIALS
During World War II, management of atypical pneumonia
was a serious problem for the United States Army, and the
Commission on Acute Respiratory Diseases of the Armed Forces
Epidemiological Board performed a series of experiments to
investigate this problem (Commission on Respiratory Diseases,
1946d). In October 1943, the Commission on Acute Respiratory
Diseases group performed a first transmission study of primary
atypical pneumonia to human volunteers (Commission on Acute
Respiratory Diseases, 1945) at Fort Bragg, North Carolina, so-
called Pinehurst area and demonstrated that unfiltered throat
washings and sputa obtained from patients early in the course of
the disease caused a respiratory illness in 10 of 12 volunteers.
Next, second and third transmission experiments were
conducted during the summer of 1944 (Commission on
Respiratory Diseases, 1946a,b,c). The inoculum consisted of
throat washings and sputum from patients admitted to Fort Bragg
Regional Hospital with atypical pneumonia. Inoculation material
was arranged into three patterns (untreated, filtered through
Corning sintered glass or Seitz filters, or autoclaved at 15 pounds
pressure for 10 min), which was introduced into the nose and
throat of each volunteer in synchronization with deep inspiration
by means of an atomizer and nebulized three times in a single
day.
In the second experiment, each group comprised 12 men,
and primary atypical pneumonia occurred equally in the filtered
(n = 4, 33.3%), untreated (n = 3, 25%), and autoclaved (n = 3,
25%) groups. The latter group was considered to be due to either
contamination of the inner surface of the air pump or cross
infection after inoculation.
The third experiment consisted of an autoclaved group
(n = 18), filtered group (n = 12), and untreated group (n = 12).
The resulting incidence of primary atypical pneumonia in each
group was 0%, 25% (n = 3), and 25% (n = 3), respectively. No
cases of pneumonia developed in healthy volunteers who received
autoclaved inoculum using rigid precautions during inoculation.
The members of the Commission on Acute Respiratory Diseases
concluded that the bacteria-free filtrates, presumably containing
a virus, could induce primary atypical pneumonia in human
volunteers.
Of note, they did not perform the following experiments:
(1) direct inoculation of Eaton agent to volunteers, (2) analysis
of inoculation materials obtained from patients with primary
atypical pneumonia, (3) preinoculation and postinoculation sera
from the Pinehurst volunteers in the chick embryo lung/hamster
neutralizing antibody assay, (4) determination of cross immunity
to Eaton agent in patients with pneumonia in the Pinehurst trial,
or (5) neutralization by pretreatment with rabbit antisera to the
Eaton agent in further volunteer experiments.
Thus, the failure of collaboration in 1944 between the
Commission on Acute Respiratory Diseases members (Dingle,
et al.) and the Eaton group left the full significance of the
Pinehurst transmission experiments unrealized for 20 years
(Table 1).
SEROLOGICAL APPROACHES FOR
IDENTIFICATION OF THE EATON AGENT
Cold Hemagglutinins
Peterson et al. (1943) reported that the development of cold
agglutinins could serve as a criterion for segregating some of
TABLE 1 | History of acceptance of the Eaton agent as a cause of primary atypical pneumonia.
Author Summary
Dienes and Edsall (1937) First isolation of Mycoplasma (Mycoplasma hominis) from humans
Reimann (1938) Recognition of symptoms of “atypical pneumonia”
Eaton et al. (1944) Discovery of Eaton agent
Commission on Acute Respiratory Diseases (1945) directed by Dingle et al. Pinehurst trials: first trial
Commission on Respiratory Diseases (1946b,c) directed by Dingle et al. Pinehurst trials: second trial
Commission on Respiratory Diseases (1946b,c) directed by Dingle et al. Pinehurst trials: third trial
Liu et al. (1959) Establishment of IF technique
Liu et al. (1959)
Chanock et al. (1960a) Eaton agent causes lower respiratory tract infection
Chanock et al. (1960b) Eaton agent grow in cell culture, monkey kidney tissue culture
Chanock et al. (1961b) Eaton agent causes lower respiratory tract infection
Clyde et al. (1961) Fluorescent-stainable antibody to the Eaton agent positive for primary atypical pneumonia
Marmion and Goodburn (1961) Eaton agent is not a virus
NIH conference (1961) Acceptance of Eaton agent as a cause of primary atypical pneumonia
Rifkind et al. (1962) Inoculation of volunteers with Eaton agent
Chanock et al. (1962a) Successful culture of the Eaton agent on cell-free medium
Chanock (1963) Taxonomic designation of M. pneumoniae
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the prevalent cases of primary atypical pneumonia until definite
etiological agents could be established. The maximum titer of
cold agglutinins (in most cases 1:160 or 1:320 at 0◦C) was
usually obtained at or near the end of the febrile period, and a
rapid decline in titer occurred during convalescence. Dingle and
Jordan demonstrated a rise in the titer of cold hemagglutinins
in over 80% of inoculated healthy volunteers who had atypical
pneumonia or a minor respiratory illness, but the titer was
elevated in only one of the patients who did not develop an illness
(Commission on Respiratory Diseases, 1946c).
Moreover, correlation of maximum cold hemagglutinin titers
with (1) extent of pulmonary involvement, (2) height and
duration of fever (Meiklejohn, 1943), and (3) other indices of
severity of illness showed no constant trends. Furthermore, Cook
et al. (1960) reported that both the hemagglutinin test and
streptococcus MG agglutinins frequently failed to develop in
patients with atypical pneumonia if the fluorescent antibody test
for the Eaton agent was positive.
Streptococcus MG Agglutinins
Serum streptococcus MG agglutinins will rise in some cases
of primary atypical pneumonia. However, the Pinehurst trial
(Commission on Respiratory Diseases, 1946c) showed that a rise
in the titer of agglutinins for streptococcus MG was not associated
with primary atypical pneumonia.
Neutralizing Antibody for Eaton’s
Pleuropneumonia-Like Organisms
Convalescent-phase sera from patients with infections caused by
Eaton’s pleuropneumonia-like organism (PPLO) had the ability
to inhibit growth of the organism (Eaton et al., 1945; Clyde, 1963).
However, this test has little diagnostic role in most instances
(Horsfall et al., 1943).
Fluorescent-Stainable Antibody for
Eaton’s PPLO
Liu (1957) described a technique which provided greater
facility in making a serologic diagnosis of Eaton agent-
related infections. Unlike cold hemagglutinins, fluorescent-
stainable antibody elevations develop in the 3rd–4th week
of illness, persist for 12–18 months, and appear to be
quite sensitive and specific (Liu et al., 1959). In 1960,
among patients with primary atypical pneumonia, Cook et al.
(1960) established a rise in Eaton fluorescent antibody (FA)
titer in 85% of 26 patients with cold and/or streptococcus
MG agglutinins and in 26% of 69 patients without cold
agglutinins.
Complement Fixation with Eaton’s PPLO
Lind et al. (1997) studied the diagnostic yield of the Complement
Fixation (CF) test using serum samples from an over 50-year
period from 1946 to 1995 in Denmark and reported that the
sensitivity and specificity of the CF test were 78 and 92%,
respectively, if the patient was considered to have a current or
recent M. pneumoniae infection when the M. pneumoniae CF
test demonstrated a ≥fourfold rise in titer to ≥64 in at least two
consecutive sera (Lind et al., 1997).
VISUALIZATION OF THE EATON AGENT
(1960s)
For many years, the agent was considered to be a virus. However,
Marmion and Goodburn (1961) successfully visualized the small
coccobacillary bodies on the mucous layer covering the bronchial
epithelium of the Eaton agent-infected chick embryo, which
suggested that the Eaton agent was not a virus.
Chanock et al. (1960b) demonstrated that propagation in
a tissue culture system was possible, but they were unable to
visualize the agent directly. In this regard, Clyde et al. (1961)
was able to subculture the tissue culture materials obtained from
infected chick embryos into monkey kidney cells and finally
visualized the brightly stained, rounded, granular structures
using Liu’s indirect fluorescent antibody procedure (Liu, 1957).
They appeared quite similar to those of the PPLO family.
Next, Chanock et al. (1962a) described the successful growth
of the Eaton agent in cell-free media, incorporating 2.5% yeast
extract and 20% horse serum. The colonies that formed on agar
were granular, with the center embedded, which occasionally
presented as a “fried egg” appearance (Figure 2) with a dense
center and a less dense periphery.
Taken together, the properties previously defined for the Eaton
agent included the following points: (1) size between 180 and
250 µm, (2) sensitivity to tetracyclines and organic gold salts, and
(3) occurrence of coccobacillary bodies on infected chick embryo
bronchial epithelium. These characteristics were consistent with
the contention that the organism was of the PPLO genus. This
accumulated evidence strongly suggested that the Eaton agent
was a member of, or shared many properties with, the genus
Mycoplasma.
FIGURE 2 | Appearance of colonies of Mycoplasma pneumoniae.
Colonies of M. pneumoniae on an agar plate typically have a unique “fried
egg” appearance.
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RE-EVALUATION OF THE EATON AGENT
AS A POSSIBLE CAUSE OF PRIMARY
ATYPICAL PNEUMONIA VIA
TRANSMISSION EXPERIMENTS TO
HUMAN VOLUNTEERS
After the Pinehurst trials, the stalemate over the acceptance of
the evidence was eventually overcome by observations of the
nature of the Eaton agent or virus and its recognition as a
mycoplasma (Marmion, 1990). However, Chanock et al. (1961b)
recovered the Eaton agent with monkey and human kidney
tissue and the transmission study was performed by coarse spray
and instillation into the noses and mouths of 52 healthy adults
(21–36 years of age) from the federal prison system. Among 52
volunteers, the Eaton agent infected all 27 seronegative volunteers
(fluorescent antibody titer prior to challenge was less than
1:10), and 17 of 25 individuals who possessed antibody (1:10 or
greater) prior to the challenge. This suggested that in the second
tissue culture passage, the Eaton agent itself was responsible for
initiating the sequence of events which led to pneumonia, otitis,
or febrile respiratory disease, irrespective of the presence of a
positive fluorescent antibody titer for the Eaton agent (Chanock
et al., 1961b; Rifkind et al., 1962).
Clyde et al. (1961) examined the preserved sera from 70
volunteers participating in two primary atypical pneumonia
transmission experiments (Pinehurst trials) with regard to
fluorescent-stainable antibodies to the Eaton agent. He found that
fluorescent-stainable antibody responses were associated with
cases of primary atypical pneumonia (Clyde et al., 1961).
In other studies, Chanock et al. (1960a) also revealed evidence
that the Eaton agent had developed in 16% of patients with
etiologically undiagnosed lower respiratory tract illness using
fluorescent-stainable antibody (Eaton antibody). Similarly, other
reports of Eaton agent–pneumonia in the 1960s showed that the
Eaton agent was certainly considered to be a cause of primary
atypical pneumonia (Chanock et al., 1961a; Evans and Brobst,
1961; Kingston et al., 1961; Goodburn et al., 1963).
TAXONOMIC DESIGNATION
M. pneumoniae
An accumulation of studies have demonstrated evidence that
the organism previously known as “primary atypical pneumonia
virus” or “Eaton agent” is not a virus (Clyde and Denny,
1963), but rather, a member of the genus Mycoplasma
(PPLO; Marmion and Goodburn, 1961; Chanock et al.,
1962a,b).
ACCEPTANCE OF THE EATON AGENT
AS A CAUSE OF ATYPICAL PNEUMONIA
In 1926, a Conference on Newer Respiratory Disease Viruses,
mycoplasmas, and PPLOs was held at the National Institutes of
Health (NIH), and Dr. Dingle finally accepted the Eaton agent as
the cause of primary atypical pneumonia (USPHS, 1962).
After being convinced of the data as described in the
paragraph of “Re-evaluation of the Eaton agent as a possible cause
of primary atypical pneumonia via transmission experiments
to human volunteers,” Chanock (1963) finally proposed the
nomenclature for the atypical pneumonia organism (Eaton
agent) as M. pneumoniae.
In the history of M. pneumoniae pneumonia, acceptance
of the Eaton agent as a cause of the disease required nearly
20 years (Clyde, 1993). Most of the pioneers were lonely and
belonged to the small scale laboratories, except for the Pinehurst
trials which were supported by numerous workers already
well known. Therefore, the delay of acceptance of the Eaton
agent possibly due to institutional or group competitiveness
(Marmion, 1990), and turned out to be a long journey for Dr.
Eaton.
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